XSTOCYXO
Market cap611kUSD
Dec 05, Last price
0.02SEK
Name
Cyxone AB
Chart & Performance
P/E
—
P/S
1.31
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.42%
Rev. gr., 5y
452.49%
Revenues
5m
-19.55%
Net income
-23m
L-45.87%
CFO
-19m
L-53.07%
Earnings
Feb 25, 2025
Profile
Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 5,148 -19.55% | 6,399 | |||||||
Cost of revenue | 2,537 | 37,990 | 34,796 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 2,611 | (31,591) | (34,796) | ||||||
NOPBT Margin | 50.72% | ||||||||
Operating Taxes | 2 | (1,000) | 3 | ||||||
Tax Rate | 0.08% | ||||||||
NOPAT | 2,609 | (31,590) | (34,799) | ||||||
Net income | (22,989) -45.87% | (42,467) -5.69% | (45,031) -8.10% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 19,972 | 60,845 | 18,188 | ||||||
BB yield | -187.36% | -120.95% | -16.25% | ||||||
| Debt | |||||||||
Debt current | 784 | 645 | |||||||
Long-term debt | 932 | 2,087 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,000 | ||||||||
Net debt | (16,152) | (26,854) | (29,376) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (19,394) | (41,323) | (43,251) | ||||||
CAPEX | (8,161) | (892) | |||||||
Cash from investing activities | (6,581) | (8,483) | (892) | ||||||
Cash from financing activities | 14,213 | 49,543 | 17,092 | ||||||
FCF | 3,113 | (33,236) | (34,799) | ||||||
| Balance | |||||||||
Cash | 17,528 | 29,246 | 29,357 | ||||||
Long term investments | 340 | 340 | 19 | ||||||
Excess cash | 17,611 | 29,266 | 29,376 | ||||||
Stockholders' equity | (203,828) | (185,583) | (145,846) | ||||||
Invested Capital | 243,648 | 233,895 | 185,077 | ||||||
ROIC | 1.09% | ||||||||
ROCE | 6.56% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 106,170 | 98,445 | 63,677 | ||||||
Price | 0.10 -80.35% | 0.51 -70.93% | 1.76 -58.54% | ||||||
Market cap | 10,659 -78.81% | 50,305 -55.06% | 111,944 -57.27% | ||||||
EV | (5,493) | 23,451 | 82,568 | ||||||
EBITDA | 5,148 | (29,350) | (33,002) | ||||||
EV/EBITDA | |||||||||
Interest | 37 | 33 | |||||||
Interest/NOPBT | 1.42% | ||||||||